Pinsheng Medical's Multi-Omics Clinical Translation Engineering Technology Research Center Receives Municipal Recognition

Recently, Pisheng Medical’s Multi-Omics Clinical Translation Engineering Technology Research Center successfully passed the annual assessment organized by the Nanjing Municipal Science and Technology Bureau, thanks to its solid infrastructure and advanced research capabilities. Among more than 100 applicant enterprises in Nanjing Jiangbei New Area, only 29 were approved (listed in no particular order). Notably, Pisheng Medical was the sole company conducting multi-omics clinical translation research using high-end medical mass spectrometers as its R&D platform, underscoring its technological advancement and industry leadership in this field.

The accreditation of Engineering Technology Research Centers emerged from the national initiative to deepen reforms in the science and technology system and strengthen the construction of technological innovation systems and capabilities. By reinforcing the intermediate links in the transformation of scientific and technological achievements, these centers enhance the maturity, compatibility, and engineering readiness of existing technologies, thereby providing technical support for large-scale corporate production. Consequently, enterprises that have obtained accreditation for Engineering Technology Research Centers represent entities whose R&D capabilities, product commercialization capacities, and economic benefits have received dual recognition from both the state and the market.

China has a large population and a vast healthcare market, yet it still lags significantly behind developed countries in high-end medical devices and advanced diagnostic and therapeutic technologies, relying heavily on imports. Multi-omics research holds tremendous potential in elucidating disease mechanisms, screening for tumor biomarkers and pathogenic targets, and enabling early diagnosis and treatment. The clinical mass spectrometry market in China is a blue-ocean market valued at hundreds of billions of yuan, urgently requiring strengthened leadership in technological innovation, accelerated import substitution, and promotion of the industry’s healthy development.

Based on the current state of industry development, Dr. Cheng Xiaoliang, founder of Pisheng Medical and inventor of the world’s first high-throughput mass spectrometry detection technology (who was selected for the 2013 R&D 100 Awards, recognizing the top 100 most commercially viable technological innovations), has been among the first researchers in China to engage with mass spectrometry and omics technologies. Since the inception of Pisheng Medical, he has led a team of elite global talents in mass spectrometry, omics research, and clinical medicine, establishing an elite multidisciplinary omics clinical translation research team. The team is dedicated to precision medicine, particularly the research and application of precision omics platforms, leveraging hard-core technological innovation to support the Healthy China initiative.

The Multi-Omics Clinical Translation Engineering Technology Research Center serves as a key pillar of Pinsheng Medical’s technological innovation system. Guided by market demands in clinical practice, laboratory diagnostics, and pharmaceuticals, the Center prioritizes scientific research and engineering technologies as its core focus, while leveraging foundational research from academic and scientific institutions as theoretical support, thereby establishing a high-end research hub that integrates industry, academia, research, and application.

Based on this, Shenzhen Institute of Life and Health Medicine Co., Ltd. will continue to increase its R&D investment in multi-omics and innovative mass spectrometry technologies, lead the process of localizing high-end mass spectrometry equipment in China, strengthen continuous innovation in clinical omics applications, constantly empower precision diagnosis and treatment, and help China catch up with and surpass international first-class levels in multiple fields such as drug development and innovative diagnostic applications.

Centered on mass spectrometry technology and driven by multi-omics research, Pinsheng Medical, as a pioneer in the translation of multi-omics research for precision medicine and the development of clinical mass spectrometry technologies in China, will remain committed to industry focus and technological innovation.

In recent years, Pinsheng Medical has successively obtained multiple prestigious certifications, including the dual quality management systems of ISO 9001 and ISO 13485, as well as a five-star after-sales service system. For several consecutive years, it has also passed the external quality assessment (EQA) conducted by the National Center for Clinical Laboratories (NCCL) under the National Health Commission with outstanding results. This demonstrates that the company’s products have reached a leading standard across the entire lifecycle, encompassing research and development, manufacturing, sales, management, and services.

Pinsheng Medical: Enhancing the Quality of Life!